China Pharmaceutical Distribution Industry Report, 2019-2025
NEW YORK, June 21, 2019 /PRNewswire/ --
China's pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017, of which drug retailing market size ranged at RMB437.7 billion in 2018, compared with RMB400.3 billion (up by 9% YoY) in 2017.
Read the full report: https://www.reportlinker.com/p02084335/?utm_source=PRN
By product, western medicine is prevailing in Chinese pharmaceutical distribution market, sweeping 73.2% of total sales in 2018; by region, the east and the central south of China take larger shares, a combined 62.1% in 2018.
In China, a competitive pattern has taken shape that national drug distributors led by Sinopharm, China Resources Pharmaceutical Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group, and regional distribution companies such as Nanjing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun Pharmaceutical, Zhejiang Int'l Group, Realcan Pharmaceutical, Guangzhou Liuzhou Pharmaceutical and Luyan Phapma, compete with each other.
By the end of 2018, there had been 13,146 drug wholesalers competing fiercely in China, showing a low market concentration. In 2018, the top 100 by operating revenue commanded 70.7% of China's pharmaceuticals market, and the first four leaders occupied 37.6%.
By the end of 2018, there had been 5,985 drugstore chains in possession of 463,200 retail stores in China, of which 242,560 were chain stores, taking up 52.4% of the total, up by 2 percentage points on an annualized basis; 88.3% of stores were directly run by retailers themselves; 72% were designated medical insurance stores.
In China, leading drug retail chains include Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd., Dashenlin Pharmaceutical Group Co., Ltd., LBX Pharmacy, Yifeng Pharmacy, Sinopharm, China Nepstar Chain Drugstore, Gansu Zhongyou Health Medicine Co., Ltd., Suzhou Quanyi Health Drugstore Chain Co., Ltd., Chongqing Tong Jun Ge Co., Ltd. and Yunnan Jianzhijia Health Drugstore Chain Co., Ltd., among which Chongqing Tong Jun Ge Co., Ltd. has 10,575 drugstores, the most among all retail chains, and Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. boasts the largest number of direct-sale stores, numbering 5,758, all of which are directly operated by the company.
The immense potential of pharmaceutical distribution industry has attracted the inrush of capital in recent years, and mergers and acquisitions occurred frequently. Boosted by capital, drug circulation companies are gearing from traditional endogenous growth by adding more products, new stores and developing customers to extensive development by M&A and restructuring. The industry is becoming increasingly concentrated.
China Pharmaceutical Distribution Industry Report, 2019-2025 highlights the following:
China pharmaceutical distribution industry (development environment, status quo, market size, market structure, competitive pattern and development trends);
China drug retailing market (market size, gross margin and net margin, quantity, share of medical insurance designated stores, per customer transaction, and comparison of operating results between major drug retailers);
20 Chinese pharmaceutical distribution companies (operation, revenue structure, gross margin, development strategy, etc.).
Read the full report: https://www.reportlinker.com/p02084335/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/china-pharmaceutical-distribution-industry-report-2019-2025-300872909.html
SOURCE Reportlinker
